Full-year 2025 total revenue reached $233.8 million, marking a 16% increase from 2024. Product revenue for full-year 2025 was $206.1 million, up 14% compared to 2024. The GAAP net loss attributable to Cerus Corporation narrowed to $15.6 million for full-year 2025, down from $20.9 million in 2024. Non-GAAP adjusted EBITDA for full-year 2025 was $9.5 million, an increase from $5.7 million in 2024, marking the second consecutive year of positive adjusted EBITDA. The company achieved its highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components in 2025. Cash, cash equivalents, and short-term investments stood at $82.9 million as of December 31, 2025. Cerus expects full-year 2026 product revenue to be in the range of $224 million to $228 million, representing 9% to 11% year-over-year growth. Included in the 2026 guidance, INTERCEPT Fibrinogen Complex (IFC) revenue is projected to be $20 million to $22 million, indicating approximately 20% to 30% year-over-year growth from 2025.